Browsing Tag
CAPVAXIVE
2 posts
Merck (NYSE: MRK) reports Q2 loss, hikes revenue view as Keytruda Qlex ramps
Merck raised 2026 sales guidance to $67.3B but cut EPS to $2.76 on Terns charge. Lipfendra approval and $463M Keytruda Qlex quarter reshape the 2028 cliff.
August 5, 2026
Can Merck sustain its oncology-led momentum? Keytruda, WINREVAIR, and pipeline drive Q3 beat
Merck’s Q3 2025 results beat expectations on Keytruda strength and a rising pipeline. Explore what’s driving EPS upgrades and future growth bets.
October 30, 2025